{
    "paper_id": "faaffa0bde0cc4f28501b1f38c1d179aff62d742",
    "metadata": {
        "title": "MISE AU POINT / UPDATE INFECTIEUX La modulation de la signature transcriptomique de l'h\u00f4te infect\u00e9 : une nouvelle strat\u00e9gie th\u00e9rapeutique dans les viroses graves ? Exemple de la grippe Modulation of Transcriptomic Signature of the Infected Host: a New Therapeutic Strategy for the Management of Severe Viral Infections? Example of the Flu",
        "authors": [
            {
                "first": "J",
                "middle": [],
                "last": "Poissy",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "\u00b7",
                "middle": [
                    "O"
                ],
                "last": "Terrier",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "\u00b7",
                "middle": [
                    "B"
                ],
                "last": "Lina",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "\u00b7",
                "middle": [
                    "J"
                ],
                "last": "Textoris",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "\u00b7",
                "middle": [
                    "M"
                ],
                "last": "Rosa-Calatrava",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "O",
                "middle": [],
                "last": "Terrier",
                "suffix": "",
                "affiliation": {},
                "email": ""
            }
        ]
    },
    "abstract": [
        {
            "text": "Ces derni\u00e8res d\u00e9cennies ont \u00e9t\u00e9 marqu\u00e9es par l'\u00e9mergence ou la r\u00e9\u00e9mergence de virus responsables d'\u00e9pid\u00e9mies ou de pand\u00e9mies plus ou moins s\u00e9v\u00e8res. Les strat\u00e9gies pr\u00e9ventives sont prises \u00e0 d\u00e9faut, et l'arsenal antiviral curatif est limit\u00e9 d'autant plus que les r\u00e9sistances virales peuvent appara\u00eetre rapidement. Par ailleurs, le d\u00e9veloppement de nouvelles mol\u00e9cules n\u00e9cessite un d\u00e9lai incompatible avec la r\u00e9ponse rapide n\u00e9cessaire lors d'une \u00e9pid\u00e9mie d'envergure ou d'une pand\u00e9mie. C'est la raison pour laquelle de nouvelles approches th\u00e9rapeutiques sont n\u00e9cessaires. Un concept novateur est le repositionnement de mol\u00e9cules d\u00e9j\u00e0 sur le march\u00e9 en exploitant leur capacit\u00e9 \u00e0 inverser la r\u00e9ponse transcriptomique cellulaire de l'h\u00f4te infect\u00e9. En identifiant des mol\u00e9cules qui visent l'h\u00f4te et non le virus, cette strat\u00e9gie permet d'avoir un large spectre d'action et d'\u00eatre potentiellement actif sur de nouveaux variants. La mise en place de cette strat\u00e9gie n\u00e9cessite de caract\u00e9riser les r\u00e9ponses cellulaires sp\u00e9cifiques de l'infection virale d'int\u00e9r\u00eat, de cribler in silico des mol\u00e9cules candidates, de les tester sur mod\u00e8les cellulaires et animaux, avant d'envisager des essais cliniques chez l'homme. Nous pr\u00e9senterons cette d\u00e9marche en prenant pour exemple l'infection grippale.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "Abstract During the last decades, emergence and reemergence of viruses were responsible for epidemic and pandemic infectious diseases, with variable degrees of severity. Current preventive strategies are not sufficient at all, and available therapeutic drugs are very limited. Indeed, genetic variations of viruses can impair the efficacy of antiviral compounds by the apparition of resistance. Moreover, current delay needed for de novo development of drugs does not allow a rapid response in case of important epidemic or pandemic events. In this context, new therapeutic approaches are necessary. An innovative concept is to repurpose already marketed compounds that can reverse the host cellular transcriptomic response to the infection. By targeting the host, these molecules exhibit a broad-spectrum activity and are potentially effective even against new emergent strains. This",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        }
    ],
    "body_text": [
        {
            "text": "R\u00e9sum\u00e9 Ces derni\u00e8res d\u00e9cennies ont \u00e9t\u00e9 marqu\u00e9es par l'\u00e9mergence ou la r\u00e9\u00e9mergence de virus responsables d'\u00e9pid\u00e9mies ou de pand\u00e9mies plus ou moins s\u00e9v\u00e8res. Les strat\u00e9gies pr\u00e9ventives sont prises \u00e0 d\u00e9faut, et l'arsenal antiviral curatif est limit\u00e9 d'autant plus que les r\u00e9sistances virales peuvent appara\u00eetre rapidement. Par ailleurs, le d\u00e9veloppement de nouvelles mol\u00e9cules n\u00e9cessite un d\u00e9lai incompatible avec la r\u00e9ponse rapide n\u00e9cessaire lors d'une \u00e9pid\u00e9mie d'envergure ou d'une pand\u00e9mie. C'est la raison pour laquelle de nouvelles approches th\u00e9rapeutiques sont n\u00e9cessaires. Un concept novateur est le repositionnement de mol\u00e9cules d\u00e9j\u00e0 sur le march\u00e9 en exploitant leur capacit\u00e9 \u00e0 inverser la r\u00e9ponse transcriptomique cellulaire de l'h\u00f4te infect\u00e9. En identifiant des mol\u00e9cules qui visent l'h\u00f4te et non le virus, cette strat\u00e9gie permet d'avoir un large spectre d'action et d'\u00eatre potentiellement actif sur de nouveaux variants. La mise en place de cette strat\u00e9gie n\u00e9cessite de caract\u00e9riser les r\u00e9ponses cellulaires sp\u00e9cifiques de l'infection virale d'int\u00e9r\u00eat, de cribler in silico des mol\u00e9cules candidates, de les tester sur mod\u00e8les cellulaires et animaux, avant d'envisager des essais cliniques chez l'homme. Nous pr\u00e9senterons cette d\u00e9marche en prenant pour exemple l'infection grippale.",
            "cite_spans": [],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "Mots cl\u00e9s Viroses \u00b7 Grippe \u00b7 Transcriptome \u00b7 Repositionnement de m\u00e9dicaments Abstract During the last decades, emergence and reemergence of viruses were responsible for epidemic and pandemic infectious diseases, with variable degrees of severity. Current preventive strategies are not sufficient at all, and available therapeutic drugs are very limited. Indeed, genetic variations of viruses can impair the efficacy of antiviral compounds by the apparition of resistance. Moreover, current delay needed for de novo development of drugs does not allow a rapid response in case of important epidemic or pandemic events. In this context, new therapeutic approaches are necessary. An innovative concept is to repurpose already marketed compounds that can reverse the host cellular transcriptomic response to the infection. By targeting the host, these molecules exhibit a broad-spectrum activity and are potentially effective even against new emergent strains. This",
            "cite_spans": [],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "Les virus ont une place pr\u00e9pond\u00e9rante en pathologie humaine. En effet, environ 15 % des 1 400 pathog\u00e8nes humains sont des virus, et 40 % de ces virus sont \u00e9mergents ou r\u00e9\u00e9mergents [1] . L'\u00e9mergence est d\u00e9finie par l'apparition d'une maladie li\u00e9e \u00e0 un agent infectieux jusque-l\u00e0 inconnu ou dont l'imputabilit\u00e9 dans la maladie n'avait pas encore \u00e9t\u00e9 mise en \u00e9vidence, ou d'un nouveau variant d'un agent connu. La r\u00e9\u00e9mergence est d\u00e9finie par la r\u00e9apparition de maladie(s) qui avai(en)t disparu ou l'augmentation de son (leur) incidence. Depuis les ann\u00e9es 1980 et \u00e0 raison de deux par an en moyenne, 87 virus ont \u00e9t\u00e9 responsables de pathologies \u00e9mergentes de gravit\u00e9 variable [2] . Les projections pr\u00e9voient l'\u00e9mergence d'une quarantaine de nouveaux virus dans les dix ans qui viennent [3] . Ces virus sont principalement des virus \u00e0 ARN \u00e0 tropisme respiratoire et dont le r\u00e9servoir est animal [2] . Les points d'orgue de ces infections virales ont \u00e9t\u00e9 l'\u00e9pid\u00e9mie de SRAS en 2003 [4] , l'apparition de la souche H1N1pdm09 en 2009 et le MERS coronavirus en 2012 [5] , du fait de leur propagation \u00e0 l'\u00e9chelle mondiale, de leur mortalit\u00e9 importante, et atteignant sp\u00e9cifiquement des populations inattendues. De mani\u00e8re plus dramatique, l'\u00e9pid\u00e9mie r\u00e9cente d'Ebola souligne davantage la n\u00e9cessit\u00e9 d'avoir \u00e0 disposition des mol\u00e9cules \u00e0 action antivirale et de pouvoir les utiliser rapidement. En effet, en dehors de l'infection par le VIH et des h\u00e9patites virales B et C, l'utilisation d'antiviraux reste tr\u00e8s limit\u00e9e et se heurte \u00e0 la probl\u00e9matique g\u00e9n\u00e9rale des r\u00e9sistances.",
            "cite_spans": [
                {
                    "start": 180,
                    "end": 183,
                    "text": "[1]",
                    "ref_id": "BIBREF0"
                },
                {
                    "start": 672,
                    "end": 675,
                    "text": "[2]",
                    "ref_id": "BIBREF1"
                },
                {
                    "start": 782,
                    "end": 785,
                    "text": "[3]",
                    "ref_id": "BIBREF2"
                },
                {
                    "start": 890,
                    "end": 893,
                    "text": "[2]",
                    "ref_id": "BIBREF1"
                },
                {
                    "start": 976,
                    "end": 979,
                    "text": "[4]",
                    "ref_id": "BIBREF3"
                },
                {
                    "start": 1057,
                    "end": 1060,
                    "text": "[5]",
                    "ref_id": "BIBREF4"
                }
            ],
            "ref_spans": [],
            "section": "Introduction"
        },
        {
            "text": "Une des approches possibles pour le d\u00e9veloppement de nouveaux antiviraux \u00e0 plus large spectre d'action est de cibler non pas le virus, mais la cellule de l'h\u00f4te infect\u00e9, en utilisant la signature transcriptomique cellulaire de l'infection pour s\u00e9lectionner et repositionner des mol\u00e9cules d\u00e9j\u00e0 sur le march\u00e9 qui vont moduler ce profil transcriptomique, suppos\u00e9 comme \u00e9tant favorable \u00e0 l'infection. Alors que cette approche est aujourd'hui d\u00e9velopp\u00e9e en canc\u00e9rologie, elle est d'utilisation tr\u00e8s r\u00e9cente en infectiologie. Nous proposons ici de pr\u00e9senter les concepts sur lesquels elle repose, en illustrant notre propos par les travaux que nous avons men\u00e9s, essentiellement sur les virus influenza.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Introduction"
        },
        {
            "text": "Les infections respiratoires aigu\u00ebs (IRA) repr\u00e9sentent une des principales causes de consultations, d'hospitalisations et de d\u00e9c\u00e8s dans le monde, \u00e9tant notamment la premi\u00e8re cause de mortalit\u00e9 chez les jeunes enfants avec pr\u00e8s de deux millions de d\u00e9c\u00e8s par an. Chaque ann\u00e9e, le co\u00fbt de leur prise en charge est estim\u00e9 entre 1,5 et 2 milliards d'euros [6] . Les progr\u00e8s en termes de diagnostic ont permis de montrer qu'une large part de ces infections est due \u00e0 des virus. Ainsi, dans une \u00e9tude \u00e9pid\u00e9miologique r\u00e9cente sur les pneumonies communautaires aux \u00c9tats-Unis n\u00e9cessitant une hospitalisation des patients, les virus repr\u00e9sentaient deux tiers des pathog\u00e8nes identifi\u00e9s. Les virus influenza de type A repr\u00e9sentaient la deuxi\u00e8me \u00e9tiologie, apr\u00e8s les rhinovirus [7] . Par ailleurs, ces virus pathog\u00e8nes respiratoires sont un facteur pr\u00e9disposant des pneumonies bact\u00e9riennes chez l'adulte [8] .",
            "cite_spans": [
                {
                    "start": 351,
                    "end": 354,
                    "text": "[6]",
                    "ref_id": "BIBREF5"
                },
                {
                    "start": 765,
                    "end": 768,
                    "text": "[7]",
                    "ref_id": "BIBREF6"
                },
                {
                    "start": 891,
                    "end": 894,
                    "text": "[8]",
                    "ref_id": "BIBREF7"
                }
            ],
            "ref_spans": [],
            "section": "\u00c9pid\u00e9miologie et enjeux des viroses respiratoires et de la grippe"
        },
        {
            "text": "Les virus influenza, responsables de la grippe, occupent donc une place pr\u00e9pond\u00e9rante parmi les agents pathog\u00e8nes responsables des IRA. Ces virus envelopp\u00e9s \u00e0 g\u00e9nome ARN segment\u00e9 font partie de la famille des Orthomyxoviridae et sont divis\u00e9s en trois types distincts, A, B et C, sur la base de leurs diff\u00e9rences majeures antig\u00e9niques, leur organisation g\u00e9nomique, leur sp\u00e9cificit\u00e9 d'h\u00f4te et leur \u00e9pid\u00e9miologie [9] . Les virus influenza A et B sont les responsables de la grippe saisonni\u00e8re. \u00c0 leur surface se trouvent deux glycoprot\u00e9ines, l'h\u00e9magglutinine (HA) qui se fixe aux r\u00e9cepteurs sialyl\u00e9s cellulaires et la neuraminidase (NA) qui permet la lib\u00e9ration des nouveaux virions. Il existe diff\u00e9rents sous-types de virus influenza A selon la nature de ces glycoprot\u00e9ines [9] . Chez l'homme, les virus circulant depuis plusieurs d\u00e9cennies sont les sous-types H1N1 et H3N2. Des transmissions interesp\u00e8ces occasionnelles, notamment de l'animal \u00e0 l'homme, sont aussi d\u00e9crites pour les virus aviaires de type H5, H7 ou H9 [10] . Ces transmissions interesp\u00e8ces \u00e0 l'origine de pand\u00e9mie r\u00e9sultent notamment de cassures antig\u00e9niques qui correspondent \u00e0 des \u00e9changes de mat\u00e9riels g\u00e9n\u00e9tiques entre soustypes viraux, conduisant \u00e0 l'apparition de virus dot\u00e9s de nouveaux antig\u00e8nes HA et NA, vis-\u00e0-vis desquels la population humaine est immunologiquement na\u00efve. Ce ph\u00e9nom\u00e8ne fut \u00e0 l'origine de l'\u00e9mergence en 2009 d'un nouveau virus grippal pand\u00e9mique H1N1, d'origine porcine, aviaire et humaine [11] , ou encore des \u00e9pid\u00e9mies de H5N1 aviaires hautement pathog\u00e8nes depuis 2003 en Asie, ou des \u00e9pisodes de grippe H7N7 aux Pays-Bas en 2003 et H7N9 dans le Sud-Est asiatique en 2013. Les \u00e9pid\u00e9mies de grippe saisonni\u00e8re sont le r\u00e9sultat d'une d\u00e9rive g\u00e9n\u00e9tique permanente des virus influenza A et B (apparition de mutations spontan\u00e9es, notamment dans les g\u00e8nes qui codent pour les glycoprot\u00e9ines de surface) [11] et constituent une cause majeure de morbidit\u00e9 et de mortalit\u00e9 accrue, notamment chez les individus tr\u00e8s jeunes, les personnes \u00e2g\u00e9es, les individus immunod\u00e9prim\u00e9s et ceux souffrant de maladies cardiopulmonaires chroniques.",
            "cite_spans": [
                {
                    "start": 410,
                    "end": 413,
                    "text": "[9]",
                    "ref_id": null
                },
                {
                    "start": 772,
                    "end": 775,
                    "text": "[9]",
                    "ref_id": null
                },
                {
                    "start": 1018,
                    "end": 1022,
                    "text": "[10]",
                    "ref_id": "BIBREF9"
                },
                {
                    "start": 1483,
                    "end": 1487,
                    "text": "[11]",
                    "ref_id": "BIBREF10"
                },
                {
                    "start": 1891,
                    "end": 1895,
                    "text": "[11]",
                    "ref_id": "BIBREF10"
                }
            ],
            "ref_spans": [],
            "section": "\u00c9pid\u00e9miologie et enjeux des viroses respiratoires et de la grippe"
        },
        {
            "text": "La grippe est une infection virale saisonni\u00e8re qui touche chaque hiver d'un \u00e0 huit millions de personnes en France, ayant un impact important non seulement en termes de sant\u00e9 publique, mais \u00e9galement d'un point de vue \u00e9conomique, en occasionnant un absent\u00e9isme (deux \u00e0 quatre millions de journ\u00e9es) et une perte de productivit\u00e9 importants. L'incidence des virus influenza dans la population est estim\u00e9e de 5 \u00e0 10 % chez les adultes et de 20 \u00e0 30 % chez les enfants. Leur taux de mortalit\u00e9 globale varie de 0,1 \u00e0 1 % selon le type de souches circulantes et la couverture vaccinale annuelle. En France, la grippe est responsable en saison hivernale de 500 \u00e0 900 consultations par semaine, avec un pic de 50 \u00e0 100 nouveaux cas graves par semaine [12] . Les admissions en r\u00e9animation pour d\u00e9tresse respiratoire associ\u00e9e \u00e0 une infection par influenza de type A sont estim\u00e9es \u00e0 12/100 000 personnes.an chez l'adulte [13] . Outre les personnes \u00e2g\u00e9es avec des comorbidit\u00e9s, les jeunes enfants et les femmes enceintes sont des populations particuli\u00e8rement \u00e0 risque. Streng et al. ont ainsi r\u00e9cemment rapport\u00e9 dans une cohorte de cas de grippe grave hospitalis\u00e9s en r\u00e9animation p\u00e9diatrique 11 % de s\u00e9quelles pulmonaires et 11 % de d\u00e9c\u00e8s [14] . Par ailleurs, dans une s\u00e9rie \u00e9pid\u00e9miologique am\u00e9ricaine ayant analys\u00e9 915 d\u00e9c\u00e8s survenus durant la saison hivernale 2009-2010 au cours d'une grossesse, il a \u00e9t\u00e9 d\u00e9montr\u00e9 que l'infection par influenza de type A \u00e9tait la cause certaine du d\u00e9c\u00e8s dans 8,2 % des cas et suspect\u00e9e dans 3,7 % [15] .",
            "cite_spans": [
                {
                    "start": 742,
                    "end": 746,
                    "text": "[12]",
                    "ref_id": "BIBREF11"
                },
                {
                    "start": 909,
                    "end": 913,
                    "text": "[13]",
                    "ref_id": "BIBREF12"
                },
                {
                    "start": 1226,
                    "end": 1230,
                    "text": "[14]",
                    "ref_id": "BIBREF13"
                },
                {
                    "start": 1519,
                    "end": 1523,
                    "text": "[15]",
                    "ref_id": "BIBREF14"
                }
            ],
            "ref_spans": [],
            "section": "\u00c9pid\u00e9miologie et enjeux des viroses respiratoires et de la grippe"
        },
        {
            "text": "La vaccination constitue la mesure pr\u00e9ventive la plus efficace contre la grippe. Cependant, le d\u00e9lai incompressible de six \u00e0 neuf mois entre le choix par l'OMS des sous-types entrant dans la composition vaccinale et la d\u00e9livrance des lots de vaccins ainsi que le manque d'adh\u00e9sion de plus en plus important de la population, y compris chez les personnels de sant\u00e9 (en France, 53 % des personnes \u00e0 risque n'\u00e9taient pas vaccin\u00e9es en 2014) limitent grandement son efficacit\u00e9 [16, 17] . Cela n'est pas sans cons\u00e9quence \u00e0 l'\u00e9chelle de la population, puisqu'un faible taux de couverture vaccinale est associ\u00e9 \u00e0 un risque augment\u00e9 d'admission en r\u00e9animation et de ventilation m\u00e9canique [18] . L'\u00e9mergence de nouveaux variants viraux par d\u00e9rive antig\u00e9nique (comme observ\u00e9 en Une strat\u00e9gie innovante d'identification de nouveaux antiviraux ciblant la cellule infect\u00e9e Transcriptome Le succ\u00e8s de telles strat\u00e9gies repose en grande partie sur notre capacit\u00e9 \u00e0 caract\u00e9riser davantage la biologie cellulaire de ces virus respiratoires et leurs interactions mol\u00e9culaires et fonctionnelles avec leur h\u00f4te. Ces derni\u00e8res ann\u00e9es, de nouvelles approches de biologie cellulaire de l'infection [38] [39] [40] [41] [42] , et en particulier le d\u00e9veloppement de la biologie des syst\u00e8mes, ont consid\u00e9rablement enrichi les connaissances concernant les interactions complexes et multiples entre ces virus et la \u00ab machinerie \u00bb cellulaire. Parmi elles, les \u00e9tudes de la r\u00e9ponse transcriptomique de l'h\u00f4te ont permis de mettre en \u00e9vidence les voies de signalisation sollicit\u00e9es et/ou d\u00e9tourn\u00e9es lors de l'infection [43, 44] . Le transcriptome correspond \u00e0 l'ensemble des ARN transcrits \u00e0 partir du g\u00e9nome cellulaire, cod\u00e9 par l'ADN [45] . Ces ARN transcrits sont compos\u00e9s d'ARN messager (ARNm), d'ARN de transfert, d'ARN ribosomal et d'ARN non codant [46] . D\u00e9terminer le transcriptome revient donc \u00e0 \u00ab photographier \u00bb l'\u00e9tat d'expression du g\u00e9nome, \u00e0 un moment donn\u00e9. Il existe diff\u00e9rentes techniques de biologie mol\u00e9culaire permettant d'analyser le transcriptome cellulaire. Cette analyse peut \u00eatre qualitative et comparative, mais aussi quantitative. Les techniques historiques (banques soustractives) sont maintenant remplac\u00e9es par des techniques dites de puces \u00e0 ADN (microarrays) ou de s\u00e9quen\u00e7age (RNAseq). Ces techniques permettent de d\u00e9terminer en une seule exp\u00e9rience l'expression transcriptomique [47] et n\u00e9cessitent l'utilisation d'outils informatiques adapt\u00e9s. Dans les r\u00e9actions inflammatoires, le profil de r\u00e9ponse transcriptomique est diff\u00e9rent selon que la cause est infectieuse ou non. Dans les infections, il a \u00e9t\u00e9 d\u00e9montr\u00e9, sur mod\u00e8le animal, qu'il \u00e9tait possible d'\u00e9tablir des r\u00e9ponses sp\u00e9cifiques du microorganisme responsable [48, 49] , faisant ainsi du transcriptome un \u00e9ventuel outil diagnostique. Cette r\u00e9ponse transcriptomique a \u00e9galement \u00e9t\u00e9 un succ\u00e8s en termes de m\u00e9decine personnalis\u00e9e dans le domaine de l'oncologie et de la prise en charge du cancer [50] . L'ensemble de ces donn\u00e9es permet d'envisager la d\u00e9termination d'une signature cellulaire sp\u00e9cifique d'une infection et d'imaginer moduler sa r\u00e9ponse.",
            "cite_spans": [
                {
                    "start": 472,
                    "end": 476,
                    "text": "[16,",
                    "ref_id": "BIBREF15"
                },
                {
                    "start": 477,
                    "end": 480,
                    "text": "17]",
                    "ref_id": "BIBREF16"
                },
                {
                    "start": 679,
                    "end": 683,
                    "text": "[18]",
                    "ref_id": "BIBREF17"
                },
                {
                    "start": 1174,
                    "end": 1178,
                    "text": "[38]",
                    "ref_id": "BIBREF36"
                },
                {
                    "start": 1179,
                    "end": 1183,
                    "text": "[39]",
                    "ref_id": "BIBREF37"
                },
                {
                    "start": 1184,
                    "end": 1188,
                    "text": "[40]",
                    "ref_id": "BIBREF38"
                },
                {
                    "start": 1189,
                    "end": 1193,
                    "text": "[41]",
                    "ref_id": "BIBREF39"
                },
                {
                    "start": 1194,
                    "end": 1198,
                    "text": "[42]",
                    "ref_id": "BIBREF40"
                },
                {
                    "start": 1586,
                    "end": 1590,
                    "text": "[43,",
                    "ref_id": "BIBREF41"
                },
                {
                    "start": 1591,
                    "end": 1594,
                    "text": "44]",
                    "ref_id": "BIBREF42"
                },
                {
                    "start": 1703,
                    "end": 1707,
                    "text": "[45]",
                    "ref_id": "BIBREF43"
                },
                {
                    "start": 1822,
                    "end": 1826,
                    "text": "[46]",
                    "ref_id": "BIBREF44"
                },
                {
                    "start": 2378,
                    "end": 2382,
                    "text": "[47]",
                    "ref_id": "BIBREF45"
                },
                {
                    "start": 2719,
                    "end": 2723,
                    "text": "[48,",
                    "ref_id": "BIBREF46"
                },
                {
                    "start": 2724,
                    "end": 2727,
                    "text": "49]",
                    "ref_id": "BIBREF47"
                },
                {
                    "start": 2952,
                    "end": 2956,
                    "text": "[50]",
                    "ref_id": "BIBREF48"
                }
            ],
            "ref_spans": [],
            "section": "Limites de la vaccination et des traitements antiviraux"
        },
        {
            "text": "Utilisation du transcriptome comme outil de d\u00e9veloppement de nouvelles approches th\u00e9rapeutiques Une des approches visant \u00e0 minimiser les r\u00e9sistances aux antiviraux tout en permettant des activit\u00e9s antivirales \u00e0 large spectre consiste \u00e0 cibler les r\u00e9ponses cellulaires de l'h\u00f4te pour contrecarrer la r\u00e9plication virale et/ou att\u00e9nuer la pathogen\u00e8se associ\u00e9e [51] . Cette strat\u00e9gie a d\u00e9j\u00e0 \u00e9t\u00e9 utilis\u00e9e avec succ\u00e8s dans les th\u00e9rapies antir\u00e9trovirales avec notamment le d\u00e9veloppement d'antagoniste de CCR5, cor\u00e9cepteur du VIH [52] .",
            "cite_spans": [
                {
                    "start": 357,
                    "end": 361,
                    "text": "[51]",
                    "ref_id": "BIBREF49"
                },
                {
                    "start": 522,
                    "end": 526,
                    "text": "[52]",
                    "ref_id": "BIBREF50"
                }
            ],
            "ref_spans": [],
            "section": "Limites de la vaccination et des traitements antiviraux"
        },
        {
            "text": "En ce qui concerne l'application de ce concept aux viroses respiratoires, Cameron et al. ont par exemple montr\u00e9 par analyse transcriptomique que l'expression du g\u00e8ne CXCL10 \u00e9tait fortement induite dans les poumons de furets infect\u00e9s par une souche hautement pathog\u00e8ne H5N1. Le traitement par un antagoniste de la voie de signalisation associ\u00e9e \u00e0 CXCL10 a permis une r\u00e9duction de la mortalit\u00e9 et de la s\u00e9v\u00e9rit\u00e9 des sympt\u00f4mes dans ce mod\u00e8le animal [43] . Par ailleurs, plusieurs m\u00e9thodes de criblage \u00e0 haut d\u00e9bit (petits ARN interf\u00e9rents [siRNA], interaction prot\u00e9ine-prot\u00e9ine) ont \u00e9t\u00e9 men\u00e9es ces derni\u00e8res ann\u00e9es et ont identifi\u00e9 plusieurs centaines de facteurs cellulaires impliqu\u00e9s dans la r\u00e9plication des virus influenza et/ou la pathogen\u00e8se associ\u00e9e \u00e0 l'infection, proposant ainsi autant de cibles th\u00e9rapeutiques potentielles [43, 44] .",
            "cite_spans": [
                {
                    "start": 446,
                    "end": 450,
                    "text": "[43]",
                    "ref_id": "BIBREF41"
                },
                {
                    "start": 829,
                    "end": 833,
                    "text": "[43,",
                    "ref_id": "BIBREF41"
                },
                {
                    "start": 834,
                    "end": 837,
                    "text": "44]",
                    "ref_id": "BIBREF42"
                }
            ],
            "ref_spans": [],
            "section": "Limites de la vaccination et des traitements antiviraux"
        },
        {
            "text": "Cependant, malgr\u00e9 des r\u00e9sultats prometteurs sur le plan exp\u00e9rimental, ce type d'approche focalis\u00e9e sur une voie pr\u00e9cise de signalisation cellulaire et un de ses effecteurs s'est pour l'instant toujours sold\u00e9e par un \u00e9chec lors de son application en clinique humaine [53, 54] , probablement du fait de la grande redondance des voies de signalisation de la cellule et de leurs interconnexions multiples.",
            "cite_spans": [
                {
                    "start": 266,
                    "end": 270,
                    "text": "[53,",
                    "ref_id": "BIBREF51"
                },
                {
                    "start": 271,
                    "end": 274,
                    "text": "54]",
                    "ref_id": "BIBREF52"
                }
            ],
            "ref_spans": [],
            "section": "Limites de la vaccination et des traitements antiviraux"
        },
        {
            "text": "Fond\u00e9e sur plusieurs \u00e9tudes assez r\u00e9centes sugg\u00e9rant que le mode d'action des m\u00e9dicaments est davantage d\u00e9pendant de leur effet transcriptionnel sur la cellule h\u00f4te que de leur interaction directe avec leur(s) cible(s) cellulaire(s) [55, 56] , nous avons mis en place un programme de recherche translationnelle visant \u00e0 exploiter la r\u00e9ponse transcriptomique de l'h\u00f4te infect\u00e9 en consid\u00e9rant le profil d'expression des g\u00e8nes cellulaires comme une empreinte globale de l'infection. Nous avons ainsi postul\u00e9 que les signatures transcriptomiques cellulaires des virus influenza refl\u00e8tent un \u00e9tat cellulaire globalement favorable \u00e0 leur r\u00e9plication, et nous avons \u00e9mis l'hypoth\u00e8se que des mol\u00e9cules associ\u00e9es \u00e0 une signature cellulaire transcriptomique inverse pourraient induire un \u00e9tat cellulaire globalement d\u00e9favorable \u00e0 l'infection. L'ensemble de cette strat\u00e9gie de repositionnement mol\u00e9culaire est sch\u00e9matis\u00e9 sur la Figure 1 . Il faut pr\u00e9ciser que dans cette approche nous ne cherchons pas \u00e0 distinguer la signature cellulaire favorisant la r\u00e9plication virale des \u00e9l\u00e9ments de la r\u00e9ponse antivirale eux aussi stimul\u00e9s lors de l'infection, car nous avons choisi d'adopter une approche globale de la cellule en sachant que les voies de signalisation, biogen\u00e8se et m\u00e9tabolique cellulaires, sont ambivalentes (\u00e0 la fois pro-et antivirales en fonction de l'\u00e9tape, du cycle infectieux et de l'\u00e9tat cellulaire). Par exemple, l'induction des voies apoptotiques par les virus influenza est \u00e0 la fois provirale dans les \u00e9tapes amont (le clivage de caspase est n\u00e9cessaire au trafic nucl\u00e9ocytoplasmique des g\u00e9nomes viraux n\u00e9osynth\u00e9tis\u00e9s) et antivirale dans les \u00e9tapes d'aval (qui sont pour le coup inhib\u00e9es par des facteurs viraux). C'est donc bien l'\u00e9tat cellulaire global auquel nous nous sommes int\u00e9ress\u00e9s. Nos premiers travaux ont permis de caract\u00e9riser des signatures transcriptomiques in vitro sp\u00e9cifiques de l'infection par diff\u00e9rents virus influenza humains et aviaires [57] [58] [59] . Il existe bien s\u00fbr des variations dans les signatures transcriptomiques entre les diff\u00e9rents sous-types viraux, mais nous nous sommes focalis\u00e9s sur les similarit\u00e9s, permettant ainsi de d\u00e9gager un profil transcriptomique commun \u00e0 tous les virus. Nous avons \u00e9galement d\u00e9velopp\u00e9 une m\u00e9thodologie d'analyse bio-informatique adapt\u00e9e \u00e0 un criblage informatique in silico permettant la s\u00e9lection de mol\u00e9cules sur la base de leur signature cellulaire anticorr\u00e9l\u00e9e \u00e0 celle de l'infection (Fig. 2) . Cette analyse repose notamment sur l'exploitation de la base de donn\u00e9es Connectivity Map [60] (Broad Institute, MIT) qui recense plus de 7 000 profils transcriptomiques obtenus apr\u00e8s traitement de cellules par 1 309 mol\u00e9cules diff\u00e9rentes, la plupart poss\u00e9dant une autorisation de mise sur le march\u00e9 pour des indications th\u00e9rapeutiques tr\u00e8s diverses (oncologie, rhumatologie, etc.). Parmi les dix mol\u00e9cules que nous avons s\u00e9lectionn\u00e9es, la pr\u00e9sence de la ribavirine, connue pour son activit\u00e9 antivi-rale [61] , a ainsi constitu\u00e9 une premi\u00e8re validation de notre strat\u00e9gie de criblage non conventionnelle. De mani\u00e8re tr\u00e8s int\u00e9ressante, les neuf autres mol\u00e9cules identifi\u00e9es dans le criblage n'\u00e9taient pas connues pour une indication th\u00e9rapeutique anti-infectieuse suppos\u00e9e. \u00c0 l'issue de leur \u00e9valuation dans diff\u00e9rents tests in vitro cellulaires sp\u00e9cifiques, nous avons pu caract\u00e9riser quatre de ces mol\u00e9cules pour leur propri\u00e9t\u00e9 antivirale \u00e0 large spectre contre plusieurs virus influenza humains et aviaires. Ces r\u00e9sultats d'efficacit\u00e9 constituaient ainsi une seconde validation de notre strat\u00e9gie de criblage et de repositionnement de m\u00e9dicaments. Ces mol\u00e9cules ont fait l'objet de deux d\u00e9p\u00f4ts de brevet d'invention (FR n o 0958810-PCT/EP2010/069023-WO 2011069990, US n o 61/279 997) pour une seconde indication th\u00e9rapeutique anti-infectieuse et ont \u00e9t\u00e9 d\u00e9crites dans une publication [57] . Parmi les mol\u00e9cules identifi\u00e9es, la midodrine, un agoniste des r\u00e9cepteurs alpha-1 adr\u00e9nergique, usuellement utilis\u00e9e comme antihypotenseur (Gutron \u00ae ) [62] , pr\u00e9sentait la meilleure activit\u00e9 antivirale \u00e0 dose non cytotoxique contre tous les virus test\u00e9s in vitro. Nous avons men\u00e9 un essai clinique multicentrique et randomis\u00e9 (essai FLUMED EUDRACT n o 011-004552-19, promoteur : hospices civils de Lyon, investigateur : Pr Bruno Lina) pour \u00e9valuer l'activit\u00e9 antivirale in vivo de cette mol\u00e9cule administr\u00e9e \u00e0 une dose usuelle de 7,5 mg/j dans la prise en charge des grippes ambulatoires, donc non s\u00e9v\u00e8res Cette \u00e9tude prospective multicentrique randomis\u00e9e en double insu comptera trois bras parall\u00e8les, afin de comparer l'efficacit\u00e9 de l'association de chacune des mol\u00e9cules \u00e0 l'oseltamivir, contre l'oseltamivir seul. Le b\u00e9n\u00e9fice attendu est une clairance virale plus rapide et plus importante que dans le groupe oseltamivir seul, avec un b\u00e9n\u00e9fice potentiel sur la dur\u00e9e de ventilation m\u00e9canique, la mortalit\u00e9, les s\u00e9quelles, notamment respiratoires. L'efficacit\u00e9 (objectif primaire) sera \u00e9valu\u00e9e sur le pourcentage de patients vivant avec une n\u00e9gativation de la charge virale influenza A (par RT-PCR) au niveau d'un \u00e9couvillon nasopharyng\u00e9 \u00e0 j7 de l'inclusion. Les objectifs secondaires seront :",
            "cite_spans": [
                {
                    "start": 233,
                    "end": 237,
                    "text": "[55,",
                    "ref_id": "BIBREF53"
                },
                {
                    "start": 238,
                    "end": 241,
                    "text": "56]",
                    "ref_id": "BIBREF54"
                },
                {
                    "start": 1966,
                    "end": 1970,
                    "text": "[57]",
                    "ref_id": "BIBREF55"
                },
                {
                    "start": 1971,
                    "end": 1975,
                    "text": "[58]",
                    "ref_id": "BIBREF56"
                },
                {
                    "start": 1976,
                    "end": 1980,
                    "text": "[59]",
                    "ref_id": "BIBREF57"
                },
                {
                    "start": 2562,
                    "end": 2566,
                    "text": "[60]",
                    "ref_id": "BIBREF58"
                },
                {
                    "start": 2976,
                    "end": 2980,
                    "text": "[61]",
                    "ref_id": "BIBREF59"
                },
                {
                    "start": 3858,
                    "end": 3862,
                    "text": "[57]",
                    "ref_id": "BIBREF55"
                },
                {
                    "start": 4016,
                    "end": 4020,
                    "text": "[62]",
                    "ref_id": "BIBREF60"
                }
            ],
            "ref_spans": [
                {
                    "start": 917,
                    "end": 925,
                    "text": "Figure 1",
                    "ref_id": "FIGREF0"
                },
                {
                    "start": 2462,
                    "end": 2470,
                    "text": "(Fig. 2)",
                    "ref_id": "FIGREF1"
                }
            ],
            "section": "Une preuve de concept : FLUMED"
        },
        {
            "text": "\u2022 de v\u00e9rifier si l'administration de ces mol\u00e9cules restaure bien un profil transcriptionnel physiologique (inversion in vivo de la signature induite par l'infection par influenza) ;",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Une preuve de concept : FLUMED"
        },
        {
            "text": "\u2022 d'\u00e9valuer l'action de ces mol\u00e9cules sur l'\u00e9volution de la charge virale (suivi pendant les dix jours du traitement) ;",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Une preuve de concept : FLUMED"
        },
        {
            "text": "\u2022 d'\u00e9valuer l'impact de ces associations sur d'autres crit\u00e8res pronostiques tels que la dur\u00e9e de ventilation m\u00e9canique, la dur\u00e9e de s\u00e9jour en r\u00e9animation et la mortalit\u00e9.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Une preuve de concept : FLUMED"
        },
        {
            "text": "Cette strat\u00e9gie innovante de criblage de mol\u00e9cules antivirales ciblant la cellule plut\u00f4t que le virus est bien adapt\u00e9e aux viroses respiratoires. Celle-ci s'inscrit dans une d\u00e9marche de repositionnement th\u00e9rapeutique. Outre les perspectives de limiter les possibilit\u00e9s d'\u00e9mergence de r\u00e9sistances, les avantages r\u00e9glementaires et financiers de cette strat\u00e9gie sont \u00e9vidents par rapport au processus long et co\u00fbteux du d\u00e9veloppement de mol\u00e9cules de novo. En perspective, il est tout \u00e0 fait envisageable que cette strat\u00e9gie rationnelle et rationalis\u00e9e que nous proposons pour cribler, s\u00e9lectionner et repositionner des m\u00e9dicaments puisse non seulement permettre de puiser dans la pharmacop\u00e9e existante et constituer ainsi une force de r\u00e9action rapide en cas d'\u00e9pid\u00e9mie ou de pand\u00e9mie, ou d'\u00e9mergence de nouveaux virus, mais \u00e9galement \u00eatre d\u00e9clin\u00e9e pour d'autres pathog\u00e8nes que ceux respiratoires cibl\u00e9s dans notre programme de recherche translationnelle. ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Perspectives"
        }
    ],
    "bib_entries": {
        "BIBREF0": {
            "ref_id": "b0",
            "title": "Risk factors for human disease emergence",
            "authors": [
                {
                    "first": "L",
                    "middle": [
                        "H"
                    ],
                    "last": "Taylor",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "M"
                    ],
                    "last": "Latham",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "E"
                    ],
                    "last": "Woolhouse",
                    "suffix": ""
                }
            ],
            "year": 2001,
            "venue": "Philos Trans R Soc Lond B Biol Sci",
            "volume": "356",
            "issn": "",
            "pages": "983--992",
            "other_ids": {}
        },
        "BIBREF1": {
            "ref_id": "b1",
            "title": "Ecological origins of novel human pathogens",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Woolhouse",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Gaunt",
                    "suffix": ""
                }
            ],
            "year": 2007,
            "venue": "Critical reviews in microbiology",
            "volume": "33",
            "issn": "",
            "pages": "231--273",
            "other_ids": {}
        },
        "BIBREF2": {
            "ref_id": "b2",
            "title": "Temporal trends in the discovery of human viruses",
            "authors": [
                {
                    "first": "M",
                    "middle": [
                        "E"
                    ],
                    "last": "Woolhouse",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Howey",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Gaunt",
                    "suffix": ""
                }
            ],
            "year": 2008,
            "venue": "Proc Biol Sci",
            "volume": "275",
            "issn": "",
            "pages": "2111--2116",
            "other_ids": {}
        },
        "BIBREF3": {
            "ref_id": "b3",
            "title": "Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection",
            "authors": [
                {
                    "first": "V",
                    "middle": [
                        "C"
                    ],
                    "last": "Cheng",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "K"
                    ],
                    "last": "Lau",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [
                        "C"
                    ],
                    "last": "Woo",
                    "suffix": ""
                }
            ],
            "year": 2007,
            "venue": "Clinical Microbiol Rev",
            "volume": "20",
            "issn": "",
            "pages": "660--94",
            "other_ids": {}
        },
        "BIBREF4": {
            "ref_id": "b4",
            "title": "Middle East respiratory syndrome",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Zumla",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "S"
                    ],
                    "last": "Hui",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Perlman",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "Lancet",
            "volume": "386",
            "issn": "",
            "pages": "995--1007",
            "other_ids": {}
        },
        "BIBREF5": {
            "ref_id": "b5",
            "title": "Addressing the public health burden of respiratory viruses: the battle against respiratory viruses (BRaVe) initiative",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Legand",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Briand",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Shindo",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "Future Virol",
            "volume": "8",
            "issn": "",
            "pages": "953--68",
            "other_ids": {}
        },
        "BIBREF6": {
            "ref_id": "b6",
            "title": "Communityacquired pneumonia requiring hospitalization among U.S. adults",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Jain",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [
                        "H"
                    ],
                    "last": "Self",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "G"
                    ],
                    "last": "Wunderink",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "N Engl J Med",
            "volume": "373",
            "issn": "",
            "pages": "415--442",
            "other_ids": {}
        },
        "BIBREF7": {
            "ref_id": "b7",
            "title": "Viral infections of the lower respiratory tract: old viruses, new viruses, and the role of diagnosis",
            "authors": [
                {
                    "first": "A",
                    "middle": [
                        "T"
                    ],
                    "last": "Pavia",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "Clin Infect Dis",
            "volume": "52",
            "issn": "",
            "pages": "284--293",
            "other_ids": {}
        },
        "BIBREF9": {
            "ref_id": "b9",
            "title": "Genome packaging in influenza A virus",
            "authors": [
                {
                    "first": "E",
                    "middle": [
                        "C"
                    ],
                    "last": "Hutchinson",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "C"
                    ],
                    "last": "Von Kirchbach",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "R"
                    ],
                    "last": "Gog",
                    "suffix": ""
                }
            ],
            "year": 2010,
            "venue": "J Gen Virol",
            "volume": "91",
            "issn": "",
            "pages": "313--341",
            "other_ids": {}
        },
        "BIBREF10": {
            "ref_id": "b10",
            "title": "Historical perspective -Emergence of influenza A(H1N1) viruses",
            "authors": [
                {
                    "first": "S",
                    "middle": [
                        "M"
                    ],
                    "last": "Zimmer",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "S"
                    ],
                    "last": "Burke",
                    "suffix": ""
                }
            ],
            "year": 2009,
            "venue": "N Engl J Med",
            "volume": "361",
            "issn": "",
            "pages": "279--85",
            "other_ids": {}
        },
        "BIBREF11": {
            "ref_id": "b11",
            "title": "Intensive care unit surveillance of influenza infection in France: the 2009/10 pandemic and the three subsequent seasons",
            "authors": [
                {
                    "first": "I",
                    "middle": [],
                    "last": "Bonmarin",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Belchior",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Bergounioux",
                    "suffix": ""
                }
            ],
            "year": 2016,
            "venue": "Euro Surveill",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF12": {
            "ref_id": "b12",
            "title": "The burden of influenza-associated critical illness hospitalizations",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "R"
                    ],
                    "last": "Ortiz",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [
                        "M"
                    ],
                    "last": "Neuzil",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "K"
                    ],
                    "last": "Shay",
                    "suffix": ""
                }
            ],
            "year": 2014,
            "venue": "Crit Care Med",
            "volume": "42",
            "issn": "",
            "pages": "2325--2357",
            "other_ids": {}
        },
        "BIBREF13": {
            "ref_id": "b13",
            "title": "Continued high incidence of children with severe influenza A(H1N1)pdm09 admitted to paediatric intensive care units in Germany during the first three post-pandemic influenza seasons",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Streng",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Prifert",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Weissbrich",
                    "suffix": ""
                }
            ],
            "year": 2010,
            "venue": "BMC Infect Dis",
            "volume": "15",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF14": {
            "ref_id": "b14",
            "title": "Pregnancyrelated mortality resulting from influenza in the United States during the 2009-2010 pandemic",
            "authors": [
                {
                    "first": "W",
                    "middle": [
                        "M"
                    ],
                    "last": "Callaghan",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "A"
                    ],
                    "last": "Creanga",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "J"
                    ],
                    "last": "Jamieson",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "Obstet Gynecol",
            "volume": "126",
            "issn": "",
            "pages": "486--90",
            "other_ids": {}
        },
        "BIBREF15": {
            "ref_id": "b15",
            "title": "Health care professionals' awareness of, knowledge about and attitude to influenza vaccination",
            "authors": [
                {
                    "first": "T",
                    "middle": [
                        "M"
                    ],
                    "last": "Alshammari",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [
                        "S"
                    ],
                    "last": "Alfehaid",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "K"
                    ],
                    "last": "Alfraih",
                    "suffix": ""
                }
            ],
            "year": 2014,
            "venue": "Vaccine",
            "volume": "32",
            "issn": "",
            "pages": "5957--61",
            "other_ids": {}
        },
        "BIBREF16": {
            "ref_id": "b16",
            "title": "Hepatitis B and influenza vaccines: important occupational vaccines differently perceived among medical students",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Wicker",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [
                        "F"
                    ],
                    "last": "Rabenau",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Von Gierke",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "Vaccine",
            "volume": "31",
            "issn": "",
            "pages": "5111--5118",
            "other_ids": {}
        },
        "BIBREF17": {
            "ref_id": "b17",
            "title": "High intensive care unit admission rate for 2013-2014 influenza is associated with a low rate of vaccination",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Catania",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [
                        "G"
                    ],
                    "last": "Que",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "A"
                    ],
                    "last": "Govert",
                    "suffix": ""
                }
            ],
            "year": 2014,
            "venue": "Am J Respir Crit Care Med",
            "volume": "189",
            "issn": "",
            "pages": "485--492",
            "other_ids": {}
        },
        "BIBREF18": {
            "ref_id": "b18",
            "title": "Midseason estimates of influenza vaccine effectiveness against influenza A(H3N2) hospitalization in the elderly in Quebec",
            "authors": [
                {
                    "first": "R",
                    "middle": [],
                    "last": "Gilca",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "M"
                    ],
                    "last": "Skowronski",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Douville-Fradet",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "PloS One",
            "volume": "10",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF19": {
            "ref_id": "b19",
            "title": "Reduced crossprotection against influenza A(H3N2) subgroup 3C.2a and 3C.3a viruses among Finnish healthcare workers vaccinated with 2013/14 seasonal influenza vaccine",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Haveri",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Ikonen",
                    "suffix": ""
                },
                {
                    "first": "I",
                    "middle": [],
                    "last": "Julkunen",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "Euro Surveill",
            "volume": "20",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF20": {
            "ref_id": "b20",
            "title": "Incidence of adamantane resistance among influenza A(H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "H"
                    ],
                    "last": "Beigel",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "A"
                    ],
                    "last": "Bright",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "J"
                    ],
                    "last": "Medina",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Xu",
                    "suffix": ""
                }
            ],
            "year": 2005,
            "venue": "Crit Care Med",
            "volume": "36",
            "issn": "",
            "pages": "1175--81",
            "other_ids": {}
        },
        "BIBREF21": {
            "ref_id": "b21",
            "title": "Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States",
            "authors": [
                {
                    "first": "R",
                    "middle": [
                        "A"
                    ],
                    "last": "Bright",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "K"
                    ],
                    "last": "Shay",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Shu",
                    "suffix": ""
                }
            ],
            "year": 2006,
            "venue": "JAMA",
            "volume": "295",
            "issn": "",
            "pages": "891--895",
            "other_ids": {}
        },
        "BIBREF22": {
            "ref_id": "b22",
            "title": "Antiviral resistance in influenza viruses--implications for management and pandemic response",
            "authors": [
                {
                    "first": "F",
                    "middle": [
                        "G"
                    ],
                    "last": "Hayden",
                    "suffix": ""
                }
            ],
            "year": 2006,
            "venue": "N Engl J Med",
            "volume": "354",
            "issn": "",
            "pages": "785--793",
            "other_ids": {}
        },
        "BIBREF23": {
            "ref_id": "b23",
            "title": "Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations",
            "authors": [
                {
                    "first": "L",
                    "middle": [],
                    "last": "Kaiser",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Wat",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Mills",
                    "suffix": ""
                }
            ],
            "year": 2003,
            "venue": "Arch Intern Med",
            "volume": "163",
            "issn": "",
            "pages": "1667--72",
            "other_ids": {}
        },
        "BIBREF24": {
            "ref_id": "b24",
            "title": "Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial",
            "authors": [
                {
                    "first": "K",
                    "middle": [
                        "G"
                    ],
                    "last": "Nicholson",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [
                        "Y"
                    ],
                    "last": "Aoki",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "D"
                    ],
                    "last": "Osterhaus",
                    "suffix": ""
                }
            ],
            "year": 2000,
            "venue": "Neuraminidase Inhibitor Flu Treatment Investigator Group",
            "volume": "355",
            "issn": "",
            "pages": "1845--50",
            "other_ids": {}
        },
        "BIBREF25": {
            "ref_id": "b25",
            "title": "Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "J"
                    ],
                    "last": "Treanor",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [
                        "G"
                    ],
                    "last": "Hayden",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [
                        "S"
                    ],
                    "last": "Vrooman",
                    "suffix": ""
                }
            ],
            "year": 2000,
            "venue": "JAMA",
            "volume": "283",
            "issn": "",
            "pages": "1016--1040",
            "other_ids": {}
        },
        "BIBREF26": {
            "ref_id": "b26",
            "title": "Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment",
            "authors": [
                {
                    "first": "F",
                    "middle": [
                        "G"
                    ],
                    "last": "Hayden",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "J"
                    ],
                    "last": "Treanor",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "S"
                    ],
                    "last": "Fritz",
                    "suffix": ""
                }
            ],
            "year": 1999,
            "venue": "JAMA",
            "volume": "282",
            "issn": "",
            "pages": "1240--1246",
            "other_ids": {}
        },
        "BIBREF27": {
            "ref_id": "b27",
            "title": "Effects of the neuraminidase inhibitor zanamavir on otologic manifestations of experimental human influenza",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "B"
                    ],
                    "last": "Walker",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [
                        "K"
                    ],
                    "last": "Hussey",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "J"
                    ],
                    "last": "Treanor",
                    "suffix": ""
                }
            ],
            "year": 1997,
            "venue": "J infect Dis",
            "volume": "176",
            "issn": "",
            "pages": "1417--1439",
            "other_ids": {}
        },
        "BIBREF28": {
            "ref_id": "b28",
            "title": "Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Mcgeer",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [
                        "A"
                    ],
                    "last": "Green",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Plevneshi",
                    "suffix": ""
                }
            ],
            "year": 2007,
            "venue": "Canada. Clin Infect Dis",
            "volume": "45",
            "issn": "",
            "pages": "1568--75",
            "other_ids": {}
        },
        "BIBREF29": {
            "ref_id": "b29",
            "title": "High-dose versus standard dose oseltamivir for treatment of severe influenza in adult intensive care unit patients",
            "authors": [
                {
                    "first": "S",
                    "middle": [
                        "C"
                    ],
                    "last": "Welch",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "W"
                    ],
                    "last": "Lam",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [
                        "A"
                    ],
                    "last": "Neuner",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "Intensive Care Med",
            "volume": "41",
            "issn": "",
            "pages": "1365--1371",
            "other_ids": {}
        },
        "BIBREF30": {
            "ref_id": "b30",
            "title": "Neuraminidase inhibitors for influenza",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Moscona",
                    "suffix": ""
                }
            ],
            "year": 2005,
            "venue": "N Engl J Med",
            "volume": "353",
            "issn": "",
            "pages": "1363--73",
            "other_ids": {}
        },
        "BIBREF31": {
            "ref_id": "b31",
            "title": "Oseltamivir resistance during treatment of influenza A(H5N1) infection",
            "authors": [
                {
                    "first": "M",
                    "middle": [
                        "D"
                    ],
                    "last": "De Jong",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [
                        "T"
                    ],
                    "last": "Tran",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [
                        "K"
                    ],
                    "last": "Truong",
                    "suffix": ""
                }
            ],
            "year": 2005,
            "venue": "N Engl J Med",
            "volume": "353",
            "issn": "",
            "pages": "2667--72",
            "other_ids": {}
        },
        "BIBREF32": {
            "ref_id": "b32",
            "title": "Avian flu: isolation of drug-resistant H5N1 virus",
            "authors": [
                {
                    "first": "Q",
                    "middle": [
                        "M"
                    ],
                    "last": "Le",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Kiso",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Someya",
                    "suffix": ""
                }
            ],
            "year": 2005,
            "venue": "Nature",
            "volume": "437",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF33": {
            "ref_id": "b33",
            "title": "Detection of human influenza A(H1N1) and B strains with reduced sensitivity to neuraminidase inhibitors",
            "authors": [
                {
                    "first": "V",
                    "middle": [],
                    "last": "Escuret",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Frobert",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Bouscambert-Duchamp",
                    "suffix": ""
                }
            ],
            "year": 2008,
            "venue": "J Clin Virol",
            "volume": "41",
            "issn": "",
            "pages": "25--33",
            "other_ids": {}
        },
        "BIBREF34": {
            "ref_id": "b34",
            "title": "Oseltamivir resistance among influenza viruses: surveillance in northern Viet Nam",
            "authors": [
                {
                    "first": "Hoang",
                    "middle": [],
                    "last": "Vu",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "P"
                    ],
                    "last": "Nguyen",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "T"
                    ],
                    "last": "Nguyen Le",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [
                        "H"
                    ],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2009,
            "venue": "Western Pac Surveill Response J (WPSAR)",
            "volume": "4",
            "issn": "",
            "pages": "25--34",
            "other_ids": {}
        },
        "BIBREF35": {
            "ref_id": "b35",
            "title": "Emergence of oseltamivir resistance: control and management of influenza before, during and after the pandemic",
            "authors": [
                {
                    "first": "R",
                    "middle": [],
                    "last": "Dixit",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Khandaker",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Ilgoutz",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "Infect Disord Drug Targets",
            "volume": "13",
            "issn": "",
            "pages": "34--45",
            "other_ids": {}
        },
        "BIBREF36": {
            "ref_id": "b36",
            "title": "The influenza fingerprints: NS1 and M1 proteins contribute to specific host cell ultrastructure signatures upon infection by different influenza A viruses",
            "authors": [
                {
                    "first": "O",
                    "middle": [],
                    "last": "Terrier",
                    "suffix": ""
                },
                {
                    "first": "V",
                    "middle": [],
                    "last": "Moules",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Carron",
                    "suffix": ""
                }
            ],
            "year": 2012,
            "venue": "Virology",
            "volume": "432",
            "issn": "",
            "pages": "204--222",
            "other_ids": {}
        },
        "BIBREF37": {
            "ref_id": "b37",
            "title": "Ultrastructural fingerprints of avian influenza A(H7N9) virus in infected human lung cells",
            "authors": [
                {
                    "first": "O",
                    "middle": [],
                    "last": "Terrier",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Carron",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Cartet",
                    "suffix": ""
                }
            ],
            "year": 2014,
            "venue": "Virology",
            "volume": "456",
            "issn": "",
            "pages": "39--42",
            "other_ids": {}
        },
        "BIBREF38": {
            "ref_id": "b38",
            "title": "Interplay between influenza A virus and the innate immune signaling",
            "authors": [
                {
                    "first": "C",
                    "middle": [],
                    "last": "Ehrhardt",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Seyer",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [
                        "R"
                    ],
                    "last": "Hrincius",
                    "suffix": ""
                }
            ],
            "year": 2010,
            "venue": "Microbes Infect",
            "volume": "12",
            "issn": "",
            "pages": "81--88",
            "other_ids": {}
        },
        "BIBREF39": {
            "ref_id": "b39",
            "title": "Development of cellular signaling pathway inhibitors as new antivirals against influenza",
            "authors": [
                {
                    "first": "O",
                    "middle": [],
                    "last": "Planz",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "Antiviral Res",
            "volume": "98",
            "issn": "",
            "pages": "457--68",
            "other_ids": {}
        },
        "BIBREF40": {
            "ref_id": "b40",
            "title": "Viral and host factors required for avian H5N1 influenza A virus replication in mammalian cells",
            "authors": [
                {
                    "first": "H",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [
                        "G"
                    ],
                    "last": "Hale",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Xu",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "Viruses",
            "volume": "5",
            "issn": "",
            "pages": "1431--1477",
            "other_ids": {}
        },
        "BIBREF41": {
            "ref_id": "b41",
            "title": "Gene expression analysis of host innate immune responses during Lethal H5N1 infection in ferrets",
            "authors": [
                {
                    "first": "C",
                    "middle": [
                        "M"
                    ],
                    "last": "Cameron",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "J"
                    ],
                    "last": "Cameron",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "F"
                    ],
                    "last": "Bermejo-Martin",
                    "suffix": ""
                }
            ],
            "year": 2008,
            "venue": "J Virol",
            "volume": "82",
            "issn": "",
            "pages": "11308--11325",
            "other_ids": {}
        },
        "BIBREF42": {
            "ref_id": "b42",
            "title": "Global host immune response: pathogenesis and transcriptional profiling of type A influenza viruses expressing the hemagglutinin and neuraminidase genes from the 1918 pandemic virus",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "C"
                    ],
                    "last": "Kash",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "F"
                    ],
                    "last": "Basler",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Garcia-Sastre",
                    "suffix": ""
                }
            ],
            "year": 2004,
            "venue": "J Virol",
            "volume": "78",
            "issn": "",
            "pages": "9499--511",
            "other_ids": {}
        },
        "BIBREF43": {
            "ref_id": "b43",
            "title": "Multifaceted mammalian transcriptome",
            "authors": [
                {
                    "first": "P",
                    "middle": [],
                    "last": "Carninci",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Yasuda",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Hayashizaki",
                    "suffix": ""
                }
            ],
            "year": 2008,
            "venue": "Curr Opin Cell Biol",
            "volume": "20",
            "issn": "",
            "pages": "274--80",
            "other_ids": {}
        },
        "BIBREF44": {
            "ref_id": "b44",
            "title": "The complex eukaryotic transcriptome: unexpected pervasive transcription and novel small RNAs",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Jacquier",
                    "suffix": ""
                }
            ],
            "year": 2009,
            "venue": "Nat Rev Genet",
            "volume": "10",
            "issn": "",
            "pages": "833--877",
            "other_ids": {}
        },
        "BIBREF45": {
            "ref_id": "b45",
            "title": "Overview of mRNA expression profiling using DNA microarrays",
            "authors": [
                {
                    "first": "F",
                    "middle": [],
                    "last": "Katagiri",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Glazebrook",
                    "suffix": ""
                }
            ],
            "year": 2009,
            "venue": "Current protocols in molecular biology",
            "volume": "22",
            "issn": "",
            "pages": "22--24",
            "other_ids": {}
        },
        "BIBREF46": {
            "ref_id": "b46",
            "title": "Human macrophage activation programs induced by bacterial pathogens",
            "authors": [
                {
                    "first": "G",
                    "middle": [
                        "J"
                    ],
                    "last": "Nau",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "F"
                    ],
                    "last": "Richmond",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Schlesinger",
                    "suffix": ""
                }
            ],
            "year": 2002,
            "venue": "Proc Natl Acad Sci",
            "volume": "99",
            "issn": "",
            "pages": "1503--1511",
            "other_ids": {}
        },
        "BIBREF47": {
            "ref_id": "b47",
            "title": "Molecular characterization of the acute inflammatory response to infections with gram-negative versus gram-positive bacteria",
            "authors": [
                {
                    "first": "R",
                    "middle": [
                        "J"
                    ],
                    "last": "Feezor",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Oberholzer",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [
                        "V"
                    ],
                    "last": "Baker",
                    "suffix": ""
                }
            ],
            "year": 2003,
            "venue": "Infect Immunity",
            "volume": "71",
            "issn": "",
            "pages": "5803--5816",
            "other_ids": {}
        },
        "BIBREF48": {
            "ref_id": "b48",
            "title": "The prognostic role of a gene signature from tumorigenic breast-cancer cells",
            "authors": [
                {
                    "first": "R",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [
                        "Y"
                    ],
                    "last": "Chen",
                    "suffix": ""
                }
            ],
            "year": 2007,
            "venue": "N Engl J Med",
            "volume": "356",
            "issn": "",
            "pages": "217--243",
            "other_ids": {}
        },
        "BIBREF49": {
            "ref_id": "b49",
            "title": "Applications of high-throughput genomics to antiviral research: evasion of antiviral responses and activation of inflammation during fulminant RNA virus infection",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "C"
                    ],
                    "last": "Kash",
                    "suffix": ""
                }
            ],
            "year": 2009,
            "venue": "Antiviral Res",
            "volume": "83",
            "issn": "",
            "pages": "10--20",
            "other_ids": {}
        },
        "BIBREF50": {
            "ref_id": "b50",
            "title": "Emerging drug targets for antiretroviral therapy",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "D"
                    ],
                    "last": "Reeves",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "J"
                    ],
                    "last": "Piefer",
                    "suffix": ""
                }
            ],
            "year": 2005,
            "venue": "Drugs",
            "volume": "65",
            "issn": "",
            "pages": "1747--66",
            "other_ids": {}
        },
        "BIBREF51": {
            "ref_id": "b51",
            "title": "Severe sepsis and septic shock",
            "authors": [
                {
                    "first": "D",
                    "middle": [
                        "C"
                    ],
                    "last": "Angus",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Van Der Poll",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "N Engl J Med",
            "volume": "369",
            "issn": "",
            "pages": "840--51",
            "other_ids": {}
        },
        "BIBREF52": {
            "ref_id": "b52",
            "title": "Sepsis: a roadmap for future research",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Cohen",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "L"
                    ],
                    "last": "Vincent",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [
                        "K"
                    ],
                    "last": "Adhikari",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "Lancet Infect Dis",
            "volume": "15",
            "issn": "",
            "pages": "581--614",
            "other_ids": {}
        },
        "BIBREF53": {
            "ref_id": "b53",
            "title": "The druggable genome",
            "authors": [
                {
                    "first": "A",
                    "middle": [
                        "L"
                    ],
                    "last": "Hopkins",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "R"
                    ],
                    "last": "Groom",
                    "suffix": ""
                }
            ],
            "year": 2002,
            "venue": "Nat Rev Drug Discov",
            "volume": "1",
            "issn": "",
            "pages": "727--757",
            "other_ids": {}
        },
        "BIBREF54": {
            "ref_id": "b54",
            "title": "Discovery and preclinical validation of drug indications using compendia of public gene expression data",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Sirota",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "T"
                    ],
                    "last": "Dudley",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Kim",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "Sci Translat Med",
            "volume": "3",
            "issn": "",
            "pages": "96--77",
            "other_ids": {}
        },
        "BIBREF55": {
            "ref_id": "b55",
            "title": "Gene expression signature-based screening identifies new broadly effective influenza a antivirals",
            "authors": [
                {
                    "first": "L",
                    "middle": [],
                    "last": "Josset",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Textoris",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Loriod",
                    "suffix": ""
                }
            ],
            "year": 2010,
            "venue": "PloS One",
            "volume": "5",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF56": {
            "ref_id": "b56",
            "title": "Cellular transcriptional profiling in human lung epithelial cells infected by different subtypes of influenza A viruses reveals an overall down-regulation of the host p53 pathway",
            "authors": [
                {
                    "first": "O",
                    "middle": [],
                    "last": "Terrier",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Josset",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Textoris",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "Virol J",
            "volume": "8",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF57": {
            "ref_id": "b57",
            "title": "Host microRNA molecular signatures associated with human H1N1 and H3N2 influenza A viruses reveal an unanticipated antiviral activity for miR-146a",
            "authors": [
                {
                    "first": "O",
                    "middle": [],
                    "last": "Terrier",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Textoris",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Carron",
                    "suffix": ""
                }
            ],
            "year": 2013,
            "venue": "J Gen Virol",
            "volume": "94",
            "issn": "",
            "pages": "985--95",
            "other_ids": {}
        },
        "BIBREF58": {
            "ref_id": "b58",
            "title": "The Connectivity Map: a new tool for biomedical research",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Lamb",
                    "suffix": ""
                }
            ],
            "year": 2007,
            "venue": "Nat Rev Cancer",
            "volume": "7",
            "issn": "",
            "pages": "54--60",
            "other_ids": {}
        },
        "BIBREF59": {
            "ref_id": "b59",
            "title": "MegaRibavirin aerosol for the treatment of influenza A virus infections in mice",
            "authors": [
                {
                    "first": "B",
                    "middle": [
                        "E"
                    ],
                    "last": "Gilbert",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "T"
                    ],
                    "last": "Mcleay",
                    "suffix": ""
                }
            ],
            "year": 2008,
            "venue": "Antiviral Res",
            "volume": "78",
            "issn": "",
            "pages": "223--232",
            "other_ids": {}
        },
        "BIBREF60": {
            "ref_id": "b60",
            "title": "Midodrine. A review of its therapeutic use in the management of orthostatic hypotension",
            "authors": [
                {
                    "first": "K",
                    "middle": [
                        "J"
                    ],
                    "last": "Mcclellan",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [
                        "R"
                    ],
                    "last": "Wiseman",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "I"
                    ],
                    "last": "Wilde",
                    "suffix": ""
                }
            ],
            "year": 1998,
            "venue": "Drugs Aging",
            "volume": "12",
            "issn": "",
            "pages": "76--86",
            "other_ids": {}
        }
    },
    "ref_entries": {
        "FIGREF0": {
            "text": "D\u00e9termination des diff\u00e9rentes signatures transcriptomiques ; a : sans infection virale ; b : en situation d'infection virale ; c : en pr\u00e9sence de la mol\u00e9cule inversant la r\u00e9ponse transcriptomique. Les graphiques correspondent \u00e0 l'\u00e9tat d'expression des g\u00e8nes sond\u00e9s par la pr\u00e9sence d'ARNm. Les g\u00e8nes surexprim\u00e9s par rapport \u00e0 l'\u00e9tat basal sont en rouge, les g\u00e8nes sous-exprim\u00e9s en vert (80 patients confirm\u00e9s comme \u00e9tant infect\u00e9s \u00e0 influenza virus A ont \u00e9t\u00e9 inclus en m\u00e9decine g\u00e9n\u00e9rale). L'objectif principal de l'essai \u00e9tait d'atteindre une efficacit\u00e9 antivirale significative 48 heures apr\u00e8s le traitement dans le bras midodrine, en comparaison du bras placebo. Les analyses de cet essai actuellement termin\u00e9 sont en cours, avec notamment une caract\u00e9risation r\u00e9trospective de la signature transcriptomique des patients trait\u00e9s, afin de d\u00e9terminer l'effet de la midodrine (vs placebo) sur le profil d'expression des g\u00e8nes en fonction de la posologie suivie et en rapport avec le tableau clinique des patients au moment de l'inclusion et de leur r\u00e9ponse au traitement. Il est important de noter que cette \u00e9tude pilote constitue la premi\u00e8re approche d'exploi-tation de signature transcriptomique pour l'identification et le repositionnement de mol\u00e9cules ayant une AMM pour une nouvelle indication th\u00e9rapeutique anti-infectieuse, incluant leur \u00e9valuation en clinique. Un essai de confirmation pour des patients plus graves : FLUNEXT Encourag\u00e9s par cette premi\u00e8re preuve de concept et dans le cadre du projet FLUNEXT (AAP DGOS/Inserm \u00ab Recherche clinique translationnelle \u00bb, investigateur principal : Dr Manuel Rosa-Calatrava) men\u00e9 avec les hospices civils de",
            "latex": null,
            "type": "figure"
        },
        "FIGREF1": {
            "text": "\u00c9tapes n\u00e9cessaires au repositionnement des mol\u00e9cules comme antiviraux, sur la base du profil transcriptomique des cellules infect\u00e9es. Les \u00e9chantillons biologiques, ici respiratoires, font l'objet d'une analyse transcriptomique. Une banque sp\u00e9cifique de signature est ainsi \u00e9labor\u00e9e. Une interrogation informatique permet d'identifier des mol\u00e9cules capables d'inverser le profil transcriptomique. Les mol\u00e9cules identifi\u00e9es sont test\u00e9es sur mod\u00e8les cellulaires et animaux Lyon, nous avons entrepris d'optimiser notre strat\u00e9gie en exploitant des \u00e9chantillons de patients hospitalis\u00e9s dans le but d'\u00e9tablir une signature transcriptomique in vivo de l'infection par le virus H1N1pdm09, renfor\u00e7ant ainsi nos chances de s\u00e9lectionner des mol\u00e9cules en th\u00e9orie plus efficaces. L'optimisation des protocoles a permis d'exploiter des \u00e9chantillons pauvres en mat\u00e9riel biologique (\u2248 10 000 cellules/5 ml ; de 500 \u00e0 70 ng d'ARN/\u00e9chantillon), issus de lavages nasaux et de liquides bronchoalv\u00e9olaires de patients infect\u00e9s. Fond\u00e9e sur l'utilisation de kits adapt\u00e9s, cette m\u00e9thodologie nous a permis d'extraire et d'amplifier les ARN totaux en qualit\u00e9 et quantit\u00e9 suffisantes pour leur analyse par microarray (puce GeneChip \u00ae Human Genome U133 plus 2.0). L'analyse fonctionnelle de la signature d'infection in vivo, et l'exploitation de la base de donn\u00e9es Connectivity Map pour un criblage in silico de mol\u00e9cules sur la base de leur signature cellulaire anticorr\u00e9l\u00e9e \u00e0 celle de l'infection, a permis d'identifier 34 compos\u00e9s candidats. La d\u00e9termination in vitro de leur concentration cytotoxique m\u00e9diane (CC50) et de leur concentration inhibitrice m\u00e9diane (IC50) a r\u00e9v\u00e9l\u00e9 des activit\u00e9s antivirales plus importantes que celles des mol\u00e9cules identifi\u00e9es dans l'\u00e9tude pilote FLUMED, validant ainsi la valeur ajout\u00e9e de la signature physiologique de l'infection, pour le criblage et la s\u00e9lection de mol\u00e9cules antivirales. Les dix meilleures candidates ont ensuite fait l'objet d'une \u00e9valuation in vivo dans un mod\u00e8le murin d'infection par le virus H1N1pdm09 (traitement par gavage). Deux mol\u00e9cules, d\u00e9j\u00e0 sur le march\u00e9 pour des indications th\u00e9rapeutiques en dehors de l'infectieux, se sont r\u00e9v\u00e9l\u00e9es particuli\u00e8rement performantes et plus efficaces que l'oseltamivir dans nos conditions exp\u00e9rimentales. En traitement \u00ab pr\u00e9challenge \u00bb, la mortalit\u00e9 viro-induite passe ainsi de 60 % dans le groupe t\u00e9moin et 40 % dans le groupe oseltamivir \u00e0 30 et 10 % respectivement pour nos deux mol\u00e9cules candidates. De plus, la combinaison de ces deux mol\u00e9cules avec l'oseltamivir pr\u00e9sente un effet additif en termes de survie, y compris dans des conditions de traitement postinfection. Ces deux mol\u00e9cules ont fait l'objet d'un d\u00e9p\u00f4t de brevet d'invention (FR 15 52284) pour une seconde indication th\u00e9rapeutique anti-infectieuse, et une publication est en pr\u00e9paration (Terrier et al.). Sur la base de ces r\u00e9sultats et gr\u00e2ce \u00e0 l'obtention d'un financement PHRCn 2015 (FLUNEXT TRIAL PHRC n o 15-0442 ; promoteur : CHU de Lille ; investigateur coordonnateur : Dr Julien Poissy), un nouvel essai clinique labellis\u00e9 par le r\u00e9seau Trial Group for Global Evaluation and Research in Sepsis (Triggersep) est pr\u00e9vu pour \u00e9valuer les propri\u00e9t\u00e9s antivirales des deux mol\u00e9cules candidates en combinaison avec l'oseltamivir chez des patients hospitalis\u00e9s en r\u00e9animation pour prise en charge d'une grippe grave.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF2": {
            "text": "Liens d'int\u00e9r\u00eats : J. Poissy n'a aucun lien d'int\u00e9r\u00eat \u00e0 d\u00e9clarer. O. Terrier d\u00e9clare \u00eatre co-inventeur des brevets cit\u00e9s dans l'article (FR n o 0958810-PCT/EP2010/069023-WO 2011069990, US n o 61/279 997). B. Lina d\u00e9clare avoir re\u00e7u un financement de Biom\u00e9rieux pour le d\u00e9veloppement d'outils diagnostiques. J Textoris d\u00e9clare \u00eatre salari\u00e9 de la soci\u00e9t\u00e9 Biom\u00e9rieux. Il est co-inventeur des brevets cit\u00e9s dans l'article (FR n o 0958810-PCT/EP2010/069023-WO 2011069990, US n o 61/279 997). M. Rosa-Calatrava d\u00e9clare \u00eatre salari\u00e9 \u00e0 l'Inserm et \u00eatre co-inventeur des brevets cit\u00e9s dans l'article (FR n o 0958810-PCT/EP2010/069023-WO 2011069990, US n o 61/279 997).",
            "latex": null,
            "type": "figure"
        }
    },
    "back_matter": []
}